Merck Says FDA Approved Labeling Update For ISENTRESS - Quick Facts - RTT News

(RTTNews) - Merck (MRK: News ) said the FDA approved a labeling update for ISENTRESS (raltegravir) Film-coated Tablets to include 156-week data from the STARTMRK study with ISENTRESS in combination therapy compared to efavirenz in combination therapy in ...

US FDA approves labelling update for Merck's Isentress - pharmabiz.com

The US Food and Drug Administration (FDA) has approved a labelling update for Merck's, known as MSD outside the United States and Canada, Isentress (raltegravir) film-coated tablets to include 156-week data from the STARTMRK study with Isentress in ...

FDA Nod for Merck Drug Label Update - Yahoo Finance

Merck (MRK) recently announced that the U.S. Food and Drug Administration (:FDA) approved a label update for its HIV therapy, Isentress. The FDA has allowed Merck to update Isentress’ label so that 156-week data from the ongoing STARTMRK study ...

FDA Nod for Merck Drug Label Update - Analyst Blog - NASDAQ

Merck ( MRK) recently announced that the U.S. Food and Drug Administration (FDA) approved a label update for its HIV therapy, Isentress. The FDA has allowed Merck to update Isentress' label so that 156-week data from the ongoing STARTMRK study ...

Walt Disney and 2 Dow 30 Stocks Making Waves - Wall St. Cheat Sheet

Merck & Co. Inc. (NYSE:MRK) has been granted FDA approval for a labeling update for Isentress Film-coated Tablets, which include 156 weeks of data from the StartMRK evaluation with Isentress, in combination therapy compared to efavirenz in combination ...

Analysis And Valuation: Johnson & Johnson, Pfizer, And Merck - Seekingalpha.com

Pharmaceutical sales are increasing, although pharma sales have been relatively flat recently. The FDA approved new labeling for Isentress (raltegravir) to include 156-week data demonstrating long-term efficacy, safety and tolerability with Isentress in ...

Gilead's Crucial AIDS Pill Gets Thumbs Up - Forbes

The medication is seen as crucial to Gilead’s future and poses a threat to Merck’s rival pill, Isentress, which must be taken twice a day. Thomas Russo, an analyst at R.W. Baird, writes: Continue to recommend overweight positions in GILD ...

Merck: Will Singulair Expiration Sink Its Stock? - Seekingalpha.com

Isentress is used in combination therapy to treat HIV infection. Gardasil is a vaccine for human papilloma virus, which causes genital warts in men and cervical and other cancers in women. Gardasil may be Merck's most interesting product. A cancer vaccine ...

AIDS Advocates to Protest Gilead over Drug Pricing at May 10th Shareholders' Meeting - Marketwatch

Chief among them is Gilead Sciences' so-called "Quad". The "Quad" combines Truvada with Elvitegravir (an integrase inhibitor similar to Merck's Isentress) and Cobicistat (a blood booster similar to the decade-old Norvir). The FDA is currently ...

Full speed ahead to curing hepatitis C - Aidsmap

Given that we already know that efavirenz causes substantial drops in boceprevir levels, HIV regimens based on raltegravir (Isentress) look like the best bet for combining with this drug. "We should have had this data earlier," stressed Renaud Persiaux of ...